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Objectives: Pseudomonas aeruginosa can cause severe lung infections in patients
with cystic ﬁbrosis, particularly in establishing a resistant structured form called
bioﬁlm. Bioﬁlm formation is mainly regulated by the communication system of the
Quorum Sensing (QS), controlled by the natural N -acyl homoserine lactones (HSL)
molecules. Thus, the aim of our study is to design potent HSL analogs to inhibit
this bioﬁlm development.
Methods: Various analogs, based on the structure of C4-HSL, were synthesized and
screened for their ability to impair bioﬁlm formation in an innovative model devel-
oped in the laboratory. Among them, compound C11 (N-pymimidyl butanamide)
showed a signiﬁcant inhibition of bioﬁlm formation in a dose-dependent manner,
coupled with an absence of cytotoxicity on lung cells. Moreover, its inhibitory
activity was preserved on a bioﬁlm developed under anaerobic conditions, set up
to approximate the in vivo colonization conditions by the bacterium. Then, C11
was tested in association with antibiotics and a signiﬁcant synergistic effect was
obtained with ciproﬂoxacin, tobramycin and colistin. After a structure-activity study
performed on C11, new analogs were synthesized and two showed an interesting
antibioﬁlm activity.
Conclusion: To improve these results, we propose to synthesize and to screen new
analogs, based on the structure of C4-HSL, and then of 3-oxo-C12-HSL, in order
to affect all QS mechanisms. Thus, this study should allow to determine the best
combination of effective molecules against the P. aeruginosa bioﬁlm and to deﬁne
optimal conditions for further in vivo investigations.
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Introduction: The development of new effective inhaled antibiotics is an important
therapeutic need. Aeroquin (AQ) is a novel levoﬂoxacin formulation for inhalation
by a customized nebulizer using eFlow technology. This Phase 3 study assessed the
efﬁcacy and safety of AQ compared to TIS in CF patients with chronic P. aeruginosa
(PA).
Methods: Randomized, open-label trial of three cycles (28-days on/28-days off)
of 240mg BID AQ vs. TIS 300mg BID. Patients were ±12 yrs, chronic PA lung
infection, FEV1 from 25−85% pred, and 3 TIS courses in the previous year.
The 1o endpoint was a non-inferiority (NI) margin of 4% in relative change in
FEV1 % pred at Day 28. 2
o endpoints included changes in absolute FEV1, CFQ-R
resp. domain, sputum PA density, and time to exacerbation, anti-PA antibiotics and
hospitalization.
Results: Of 282 patients enrolled, 272 were dosed, 33 (11.7%) discontinued. Mean
patient baseline age was 28.5 yr; FEV1 was 54.5% predicted. Patients averaged 5.9
inhaled antibiotic courses in the previous year. The 1o endpoint of NI was met; the
LS mean difference in relative change in FEV1% pred between groups at Day 28
was 1.86% in favor of AQ (95% CI −0.66, 4.39). Similar results were observed at the
end of treatment at Days 84 and 140. AQ resulted in longer time to need for anti-PA
antibiotics and greater CFQ-R respiratory domain scores. No statistical signiﬁcance
between groups was observed for time to exacerbation (Fuchs) or hospitalization.
Group AE and SAE incidence was similar.
Conclusion: The primary endpoint of NI comparing AQ to TIS was met. These
data suggest AQ has a similar therapeutic effect to TIS which is sustained over 3
treatment cycles.
